HSD119 Persistence to Treatment with Initially Prescribed Antiplatelet Agents for the Onset of Acute Coronary Syndrome

Abstract

Oral antiplatelet agent (OAA) is a medication class that reduces complications after the onset of acute coronary syndrome (ACS). The addition of 3rd-generation OAAs (3G-OAA: prasugrel and ticagrelor) on top of the historic standard strategy, clopidogrel, has enabled physicians to contemplate switching among therapies for specific clinical and financial circumstances. This study aimed to describe the persistence on and switching from the initially prescribed OAA after the onset of ACS.